Glofitamab [Columvi]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
No
Active ingredient: Glofitamab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion, for use in combination with gemcitabine and oxaliplatin, for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant.
Funding status
[R] Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
Clinical indication, subsidy class and MediShield Life claims eligibility for glofitamab are provided in the Annex.
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for glofitamab are provided in the Annex.
Post Marketing Information
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Intravenous
* Clinical information is available for this product.